Indeed, a recent study has reported that the co-inhibition of SHP2 and KRAS in xenograft models is effectively able to suppress feedback reactivation of KRAS pathway, producing a significant tumor shrinkage (35). This evidence concerns the gene KRAS and neoplasm.